KR102501566B1 - 병용 기반 치료 방법 - Google Patents

병용 기반 치료 방법 Download PDF

Info

Publication number
KR102501566B1
KR102501566B1 KR1020167020229A KR20167020229A KR102501566B1 KR 102501566 B1 KR102501566 B1 KR 102501566B1 KR 1020167020229 A KR1020167020229 A KR 1020167020229A KR 20167020229 A KR20167020229 A KR 20167020229A KR 102501566 B1 KR102501566 B1 KR 102501566B1
Authority
KR
South Korea
Prior art keywords
days
inhibitor
long
topoisomerase
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167020229A
Other languages
English (en)
Korean (ko)
Other versions
KR20160106086A (ko
Inventor
우테 호흐
낸시 매리 번즈
데보라 에이치 체리치
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52469293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102501566(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20160106086A publication Critical patent/KR20160106086A/ko
Application granted granted Critical
Publication of KR102501566B1 publication Critical patent/KR102501566B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020167020229A 2014-01-14 2015-01-13 병용 기반 치료 방법 Active KR102501566B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461927376P 2014-01-14 2014-01-14
US61/927,376 2014-01-14
US201462080775P 2014-11-17 2014-11-17
US62/080,775 2014-11-17
PCT/US2015/011239 WO2015108876A1 (en) 2014-01-14 2015-01-13 Combination-based treatment method

Publications (2)

Publication Number Publication Date
KR20160106086A KR20160106086A (ko) 2016-09-09
KR102501566B1 true KR102501566B1 (ko) 2023-02-17

Family

ID=52469293

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167020229A Active KR102501566B1 (ko) 2014-01-14 2015-01-13 병용 기반 치료 방법

Country Status (8)

Country Link
US (2) US10653689B2 (https=)
EP (1) EP3094331B1 (https=)
JP (1) JP6758195B2 (https=)
KR (1) KR102501566B1 (https=)
AU (1) AU2015206667B2 (https=)
CA (1) CA2934552C (https=)
MX (1) MX386070B (https=)
WO (1) WO2015108876A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102611382B1 (ko) 2018-09-19 2023-12-07 삼성디스플레이 주식회사 터치 감지 유닛과 그를 포함하는 표시 장치
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629696T3 (es) * 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
EP1793830A2 (en) * 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
JP2006124351A (ja) 2004-11-01 2006-05-18 Yakult Honsha Co Ltd 徐放性抗腫瘍剤組成物
ME02121B (me) * 2006-01-17 2014-06-30 Abbvie Ireland Unlimited Co Kombinovana terapija sa parp inhibitorima
TWI426905B (zh) 2006-02-09 2014-02-21 安龍製藥公司 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
WO2008147418A1 (en) 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CA2708157A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
ME03396B (me) 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Also Published As

Publication number Publication date
CA2934552C (en) 2021-03-30
MX386070B (es) 2025-03-18
EP3094331A1 (en) 2016-11-23
US20160339013A1 (en) 2016-11-24
MX2016009167A (es) 2016-09-09
US10653689B2 (en) 2020-05-19
KR20160106086A (ko) 2016-09-09
EP3094331B1 (en) 2017-12-27
US20200237747A1 (en) 2020-07-30
JP2017502091A (ja) 2017-01-19
CA2934552A1 (en) 2015-07-23
AU2015206667B2 (en) 2020-05-14
WO2015108876A1 (en) 2015-07-23
AU2015206667A1 (en) 2016-07-07
JP6758195B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
EP3337478B2 (en) Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer
RU2761953C2 (ru) Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
JP6076317B2 (ja) 対象において持続的治療薬濃度を実現するための組成物及び方法
EP3600341A1 (en) Gemcitabine derivatives for cancer therapy
CA2644297A1 (en) Prevention and treatment of cancer and other diseases
WO2010121455A1 (zh) 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
US20200237747A1 (en) Combination-based treatment method
WO2014159774A1 (en) Custirsen treatment with reduced toxicity
EP2771034B1 (en) Topoisomerase-i and-ii inhibitors for use in the treatment of patients suffering from cancer
US20130296407A1 (en) Combination Therapy for Cancer
CN109789136B (zh) 用于预防或治疗结肠直肠癌的药物联合组合物
TW202019440A (zh) 用於治療癌症之組合療法
Zhao EZN-2208 (PEG-SN38), a 40 kda polyethylene glycol (peg) conjugate, as an anticancer agent: review of preclinical and clinical data
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK40045473A (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
EP1229938B1 (en) Potentiation of the activity of sn-38 prodrugs
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法
JP2010207109A (ja) 炎症性腸疾患の治療剤及びそれに用いられるポリヌクレオチド
HK1257250B (en) Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer
HK1155378A (en) Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191209

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210315

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220119

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221115

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230215

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230215

End annual number: 3

Start annual number: 1

PG1601 Publication of registration